Navigation Links
AcelRx Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
Date:8/10/2011

REDWOOD CITY, Calif., Aug. 10, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at the Canaccord Genuity Growth Conference in Boston, MA at the InterContinental Hotel. The presentation is scheduled for Thursday, August 11, 2011 at 8:00 a.m. ET.  

The presentation will be webcast live and can be accessed through http://wsw.com/webcast/canaccord4/acrx/.  For those who are not available to listen to the live broadcast, the presentation will be archived and available through http://www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild seda
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... YORK , Feb. 26, 2015 ... Latin America is estimated at 2.4 ... said that population growth, government insurance, newly insured ... in the region and will continue to propel ... on torresearch into the market and interviews with ...
(Date:2/26/2015)... BOSTON , Feb. 26, 2015 ... ("Columbia" or "the Company"), a specialty pharmaceutical company ... health, plans to initiate a Phase II clinical ... in women undergoing transvaginal pipelle-directed endometrial biopsy in ... pre-Investigational New Drug ("IND") submission feedback from the ...
(Date:2/26/2015)... Feb. 26, 2015  Technological advancements have ... effective, inexpensive and compact yet powerful solutions. ... small-scale, potent devices, lending momentum to the ... http://photos.prnewswire.com/prnh/20150225/177944LOGO New ... Nanomanufacturing, finds that nanomanufacturing will gain traction ...
Breaking Medicine Technology:Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 3Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 4Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 2Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 3Revolutionary Nanomanufacturing Technology to Approach Commercialization by 2020 2Revolutionary Nanomanufacturing Technology to Approach Commercialization by 2020 3Revolutionary Nanomanufacturing Technology to Approach Commercialization by 2020 4
... II Study Demonstrates Significant,Additional Improvement for Patients ... /PRNewswire-FirstCall/ --,Indevus Pharmaceuticals, Inc. today announced that ... for pagoclone in persistent,developmental stuttering will be ... the New Clinical Drug Evaluation Unit (NCDEU), ...
... Insomnia on Healthcare System and,Worker Productivity, SAN ... Inc. announced today that results from several,research ... and transient,insomnia were presented this week at ... APSS highlights show that,insomnia is significantly under-diagnosed ...
Cached Medicine Technology:Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 2Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 3Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 4Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 5Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 7Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 8Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 9Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 2Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 3Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 4Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 5
(Date:2/27/2015)... 2015 The report “Polycystic Ovarian ... information on the therapeutic development for polycystic ovarian ... which a woman's hormones are out of balance. ... teenage girls and young women. The cause of ... R&D pipelines by identifying new targets and MOAs ...
(Date:2/27/2015)... 2015 If there is one thing that ... a head lice outbreak at their child’s school. While head ... parasite is nothing short of a nightmare for many parents ... their children, or within their child’s classroom. Just when they ... starts scratching again. , Local lice removal company, Lice ...
(Date:2/27/2015)... February 27, 2015 Qualis Health, ... organizations, has been named a finalist in the ... recognition of outstanding commitment toward continuous improvement in ... in reducing hospital readmission rates through its Communities ... are honored to receive this national recognition, which ...
(Date:2/27/2015)... 27, 2015 A fireplace can cause the ... its heat through the chimney’s flue when the fireplace is ... Tamarack Technologies has solved with the introduction of a new ... PVC pillow measuring 18" in diameter when inflated. It is ... just below the damper. This size unit fits into round ...
(Date:2/27/2015)... 27, 2015 The Connecticut Community for ... along with Alcohol and Drug Recovery Centers (ADRC), for ... these organizations were honored with the 2014 Commissioner’s Recognition ... Addiction Services. Last year, ROES achieved the ... people who are recovering from alcoholism and other drug ...
Breaking Medicine News(10 mins):Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 3Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 4Health News:Anxiety over head lice among Miami parents as surge in head lice cases reported by local lice removal company Lice Troopers 2Health News:Qualis Health Named Award Finalist for Care Transitions Work 2Health News:New DraftStopper from Tamarack Technologies Stops Heat Loss When Fireplace Not in Use 2
... risk of bacterial disease in valves at bay , , MONDAY, ... and gums may be crucial in preventing heart valve infection, ... activities such as brushing were as likely as major dental ... a dangerous infection of the lining of the heart or ...
... 9 MINRAD,International, Inc. (Amex: BUF ) ... Food and Drug Administration Center for Veterinary Medicine,to ... initiated their US product launch to the veterinary ... Inc. is an interventional pain management company,with real-time ...
... Medical Credit Crisis, YONKERS, N.Y., June 9 ... including GE Money, Citigroup, and,Chase, are pushing risky credit ... Consumer Reports, which describes the new lending,practices as akin ... covering medical costs: at about $45 billion today, it ...
... Repair, Inc.,(ICR), headquartered in Warren, Michigan, received the ... delivery of MRO Asset Management and,industrial repair services. ... solutions and selling refurbished,industrial equipment to customers around ... the annual Honda of America Manufacturing,MRO Supplier Conference ...
... findings don,t account for overall health factors and intelligence ... are more prone to memory problems than their non-smoking ... is a recognized health hazard, there has been some ... said. , "Dementia is rare among middle-aged people, but ...
... of,Labor & Industry invites the public to learn more about ... Safety Day from 10 a.m. to 2,p.m. on Wednesday, June ... event will feature an array of interactive services promoting,health and ... can,receive - free of charge - relaxing massages; a cool ...
Cached Medicine News:Health News:Good Oral Hygiene May Protect Against Heart Infections 2Health News:MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane 2Health News:Consumer Reports: Patients 'Overdose' on Debt As Lenders, Doctors, and Hospitals Push Risky Credit to Pay for Medical Care 2Health News:Consumer Reports: Patients 'Overdose' on Debt As Lenders, Doctors, and Hospitals Push Risky Credit to Pay for Medical Care 3Health News:Consumer Reports: Patients 'Overdose' on Debt As Lenders, Doctors, and Hospitals Push Risky Credit to Pay for Medical Care 4Health News:Industrial Control Repair Named Honda of America Manufacturing's '2007 Supplier of the Year' 2Health News:Smoking Tied to Memory Loss in Middle Age 2Health News:Smoking Tied to Memory Loss in Middle Age 3
... difficile Panel is an enzyme immunoassay used ... antigen (glutamate dehydrogenase) and toxin A in ... as an aid in the diagnosis of ... of the Triage Microbiology product line, designed ...
ELISA for the detection of C. difficile toxin A in stool specimens...
... CCD cameras provide fast, accurate, reliable and ... quality at an excellent price. , , ... TOMEY TR-4000 Auto Refractor provides highly accurate ... is obtained simply by pushing a button. ...
... SP-3000 covers all needs regarding pachymetry in ... care., ,Compact design, colored touch-screen and "quick ... an "easy-to-use unit.,The wide measurement range from ... the possibility to measure very thin or ...
Medicine Products: